Comments
Shares of Lupin are likely to remain in focus on Friday, as the pharma major said it has received an approval from the US Food and Drug Administration to sell generic version of gastric ulcer drug Prilosec Delayed-Release capsules. In a stock market disclosure, Lupin said Prilosec had sales of $185 million (about ₹1,220 crore) in the US for the 12-month period ended June. The approval is Lupin’s third from the US in the last five days.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.